Personal care compositions for malodor control and methods thereof

Abstract

The present disclosure is directed towards compositions and methods for personal care malodor control. More specifically, the present disclosure relates to compositions comprising a Brevibacillus laterosporus fermentate extract, or fraction thereof, for body malodor control and methods of use thereof. Compositions containing the Brevibacillus laterosporus fermentate extract are suitable for use as underarm / axillary deodorants, and for malodor control in personal care applications.

Description

[0001]TITLE PERSONAL CARE COMPOSITIONS FOR MALODOR CONTROL AND METHODS THEREOF CROSS REFERENCE OF RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 490,569, filed March 16, 2023, the entire content which is hereby incorporated by reference. FIELD OF THE DISCLOSURE The present disclosure is directed towards personal care compositions for malodor control on body surfaces and methods thereof. More specifically, the present disclosure relates to compositions comprising a Brevibacillus laterosporus fermentate extract, or fraction thereof, for preventing and / or reducing malodor on body surfaces and methods of use thereof. Compositions containing the Brevibacillus laterosporus fermentate extract are suitable for use as deodorant compositions, and cosmetic compositions for malodor control. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY The content of the sequence listing electronically submitted with the application as an XML file (20240213_NB42196PCT_sequencelisting; Size: 36,960 bytes; Created: February 13, 2024) forms part of the application and is hereby incorporated herein by reference in its entirety. BACKGROUND Human axillary secretions (sweat) are often odorless. The axillary malodor production is mainly due to biotransformation of odorless secreted molecules by the microorganisms residing in the axillary region. Based on phylogenetic analysis, a variety of microbes are present in the axillary areas (Troccaz, et al., Microbiome 3, 3, 2015; James, et al., FEMS Microbiol Ecol., 2013,83(3):527-540; Rudden, et al., Sci Rep.2020, 10:12500). Staphylococcus species is one of the major group of microbes responsible for the production of axillary odorous compounds. It has long been desired to prevent body malodor (such as axillary malodor). Mechanisms to provide deodorancy include applying anti-bacterial substances to the axillary skin, providing perfume compositions capable of masking malodour, and trapping malodorous molecules (for example by applying cyclodextrin, for inhibiting β-lyases). Ethylenediaminetetraacetic acid (EDTA) and other metal sequestering agents, can also be used as deodorant active ingredients, which act to remove critical metal nutrients required by bacteria for enzymic formation of free acids. In the cosmetic field, it is well known to use astringent salts, such as aluminum and / or zirconium salts, as antiperspirants, which have the effect of limiting or even eliminating the flow of sweat. Some people find that the application of products containing these metal salts causes skin irritation. Consumers’ demand for formulations using ingredients from renewable sources has been steadily increasing in recent years, prompting more investigations into solutions of replacing existing ingredients with sustainable alternatives while still providing products with appealing characteristics and performance. There remains a need to search for effective and environmentally friendly and sustainable solutions for mitigating malodor on body surfaces, which are effective in terms of malodor control performance, are easily formulated and well tolerated by users. SUMMARY The present disclosure is directed towards compositions comprising Brevibacillus laterosporus fermentate extracts for personal care malodor control and methods of use thereof. More specifically, the present disclosure is directed towards compositions comprising at least one Brevibacillus laterosporus fermentate extract, or fraction thereof, and methods for providing malodor control in personal care applications. The present invention is based on the discovery that fermentate extracts from Brevibacillus laterosporus function as a malodor control component. In one aspect, the inventors have unexpectedly observed that an effective amount of a Brevibacillus laterosporus fermentate extract functions as a malodor control agent to prevents and / or reduces body malodor such as axillary malodor and foot malodor. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface. In one aspect, the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface, wherein the body surface is selected from the group consisting of an axillary region of the body, skin, foot, hair, and scalp. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface, wherein the composition is a personal care or cosmetic composition. In one embodiment, the composition is a deodorant composition for preventing or reducing body malodor, comprising, as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said effective amount of extract prevents and / or reduces a malodor on said body surface, and wherein the ingredient is incorporated in a vehicle for a deodorant. In one embodiment, the method is a method of preventing or reducing a malodor from a body surface, comprising the step of applying an effective amount of a Brevibacillus laterosporus fermentate extract, or a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract to said body surface, wherein said extract prevents and / or reduces said malodor on said body surface. In one embodiment, the method is a method of preventing or reducing a malodor from a human or animal surface, such as an axillary region of the body or a foot, comprising the step of applying an effective amount of a Brevibacillus laterosporus fermentate extract, or a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract to said surface, wherein said extract prevents and / or reduces said malodor on said surface. DETAILED DESCRIPTION The features and advantages of the present disclosure will be more readily understood, by those of ordinary skill in the art from reading the following detailed description. It is to be appreciated that certain features of the disclosure, which are, for clarity, described above and below in the context of separate embodiments, may also be provided in combination in a single element. Conversely, various features of the disclosure that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination. It will be understood that in the following, embodiments referred to in relation to one broad aspect of the invention are equally applicable to each of the other broad aspects of the present invention described above. It will be further understood that, unless the context dictates otherwise, the embodiments described below may be combined. Microorganisms, Fermentates, and Fermentate Extracts As used herein, "microorganism" or “microbe” refers to a bacterium, a fungus, a virus, a protozoan, archaea, and other microbes or microscopic organisms. In some embodiments, the microorganism(s) suitable for use in the present invention can be subjected to treatments that render them non- replicating, for example, exposure to heat, desiccation, γ-irradiation, or UV- irradiation. A non-replicating microorganism(s) suitable for use in the present invention can be a dead cell or a living cell that has been rendered incapable of cell division. A non-replicating microorganism(s) suitable for use in the present invention can be an intact cell or a cell that has undergone partial or complete lysis. In some embodiments, the non-replicating cells can include a mixture of intact and lysed cells. The microorganism(s) suitable for use in the present invention may be included in a composition according to the invention in live, semi-active or inactivated or dead form. For the purposes of the invention, an “inactivated” or “dead” microorganism is a microorganism that is no longer capable of forming colonies in cultures. The dead or inactivated microorganisms may have intact or broken cell membranes. The dead or inactivated microorganisms may be obtained via any method known to those skilled in the art. The microorganisms suitable for use in the present invention includes a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108. The phylogenetic identity of Brevibacillus laterosporus was determined by sequencing the 16S region with primer set A (5´- GTGCCAGCMGCCGCGGTAA -3, SEQ ID NO: 2) and primer set B (5′- CGGTTACCTTGTTACGACTT, SEQ ID NO: 3). The 16S ribosomal RNA sequence of Brevibacillus laterosporus G2 (SEQ ID NO: 1) is as follows: UGCAGUCGAGCGAGGGUCUUCGGACCCUAGCGGCGGACGGGUGA GUAACACGUAGGCAACCUGCCUGUAAGACUGGGAUAACAUAGGGAAACU UAUGCUAAUACCGGAUAGGGUUUUGCUUCGCCUGAAGCGAAACGGAAAG AUGGCGCAAGCUAUCACUUACAGAUGGGCCUGCGGCGCAUUAGCUAGU UGGUGAGGUAAUGGCUCACCAAGGCAACGAUGCGUAGCCGACCUGAGA GGGUGACCGGCCACACUGGGACUGAGACACGGCCCAAACUCCUACGGG AGGCAGCAGUAGGGAAUUUUCCACAAUGGACGAAAGUCUGAUGGAGCAA CGCCGCGUGAACGAUGAAGGCUUUCGGGUCGUAAAGUUCUGUUGUUAG GGAAGAAACAGUGCUAUUUAAAUAAGGUAGCACCUUGACGGUACCUAAC GAGAAAGCCACGGCUAACUACGUGCCAGCAGCCGCGGUAAUACGUAGGU GGCAAGCGUUGUCCGGAAUUAUUGGGCGUAAAGCGCGCGCAGGUGGCU AUGUAAGUCUGAUGUUAAAGCCCGAGGCUCAACCUCGGUUCGCAUUGGA AACUGUGUAGCUUGAGUGCAGGAGAGGAAAGUGGUAUUCCACGUGUAG CGGUGAAAUGCGUAGAGAUGUGGAGGAACACCAGUGGCGAAGGCGACU UUCUGGCCUGUAACUGACACUGAGGCGCGAAAGCGUGGGGAGCAAACA GGAUUAGAUACCCUGGUAGUCCACGCCGUAAACGAUGAGUGCUAGGUG UUAGGGGUUUCAAUACCCUUAGUGCCGCAGCUAACGCAAUAAGCACUCC GCCUGGGGAGUACGCUCGCAAGAGUGAAACUCAAAGGAAUUGACGGGG GCCCGCACAAGCGGUGGAGCAUGUGGUUUAAUUCGAAGCAACGCGAAG AACCUUACCAGGUCUUGACAUCCCACUGACCGCUCUAGAGAUAGAGCUU CCCUUCGGGGCAGUGGUGACAGGUGGUGCAUGGUUGUCGUCAGCUCGU GUCGUGAGAUGUUGGGUUAAGUCCCGCAACGAGCGCAACCCUUAUCUU UAGUUGCCAGCAUUCAGUUGGGCACUCUAGAGAGACUGCCGUCGACAA GACGGAGGAAGGCGGGGAUGACGUCAAAUCAUCAUGCCCCUUAUGACC UGGGCUACACACGUGCUACAAUGGUUGGUACAACGGGAUGCUACUUCG CGAGAAGAUGCUAAUCUCUUAAAACCAAUCUCAGUUCGGAUUGUAGGCU GCAACUCGCCUACAUGAAGUCGGAAUCGCUAGUAAUCGCGGAUCAGCAU GCCGCGGUGAAUACGUUCCCGGGCCUUGUACACACCGCCCGUCACACC ACGGGAGUUUGCAACACCCGAAGUCGGUGAGGUAACCGCAAGGAGCCA GCCGCCGA The microorganisms suitable for use in the present invention includes, but are not limited to, a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. In one aspect of the invention, fermentates are provided. As used herein, the term "fermentate" is to be understood as a composition (complex mixture) produced by propagating living microorganisms (microbial strains) in a nutrient medium. The fermentate may include a cellular mass component from said microorganisms, unspent media components, and metabolites (i.e., unused substrates and / or fermentation end-products). As used herein, a “cellular mass component” refers to any mixture of proteins, lipids (i.e., membranes), carbohydrates, exopolysaccharides, metabolites, etc. from the propagated microorganism. For example, as a microorganism grows it produces new cells that generally include additional cellular mass such as, without limitation, cell membranes, nucleic acids (i.e., DNA and / or RNA) internal subcellular structures, polysaccharides, and proteins (i.e., membrane-bound, secreted, and / or intracellular). Fermentates for use in the present invention include fermentates from the microorganism Brevibacillus laterosporus. The growth medium used for preparing the fermentate is any medium comprising necessary nutrients suitable for propagating the microorganism(s) suitable for use in the present invention. Suitable nutrients include but are not limited to amino peptides, peptides, yeast extract, salts, sugars, carbohydrates and / or vitamins. The medium can be based on dairy products, such as milk, cereals, fruits and / or vegetables. In one aspect, the fermentates for use in the present invention includes fermentates from the microorganism Brevibacillus laterosporus, wherein said Brevibacillus laterosporus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non- sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. Fermentates can be further concentrated prior to be included in a composition to obtain an effective amount of actives in said fermentate. Fermentate extracts can be produced from the fermentates as described herein, Fermentates can be spray-dried or lyophilized prior to be include in a composition. It will be apparent that the fermentate may be used directly in the compositions and methods of the present invention, or that one or more fractions or extracts from said fermentate comprising actives may be isolated form the fermentate by any suitable means prior to use. In one aspect of the invention, fermentate extracts are provided. Fermentate extracts for use in the present invention include fermentates from the microorganism Brevibacillus laterosporus. As used herein, the term "fermentate extract” refers to an extract or fraction from a fermentate, wherein the fermentate was produced by propagating living microorganisms (microbial strains) in a nutrient medium as described above. In one aspect the fermentate extract is an extract of a fermentate produced by propagating of a Brevibacillus laterosporus species. In one aspect, the fermentate extract is a cell free supernatant of a fermentate. As used herein, a “cell free supernatant” ,“fermentate supernatant”, “cell free fermentate” or “fermentate filtrate” are used interchangeably and refer to a fermentate extract that is substantially free of viable cells, such as a supernatant of a cell culture of at least one microorganism from which the cells have been removed. It is understood that cells can be removed from the cell culture by any method known in the art and that such removal of cells (such as through centrifugation, filtration) may still result in cell free supernatants that can comprise a trace amount of cells or cell debris. Methods for separating cells from growth media are well known in the art and can rely upon physical methods, for example, centrifugation to produce a cell pellet and a culture supernatant, filtration, ultrafiltration, tangential flow-filtration, normal flow filtration or reverse osmosis. Alternatively, or in addition, the separation method can be ligand-based and include, for example, an antibody that specifically binds to Brevibacillus laterosporus. The antibody can be coupled to a solid support such as a magnetic bead. In one embodiment the cell free supernatant is obtained by filtration or centrifugation of the culture medium in which Brevibacillus laterosporus cells were cultivated. In one aspect, the cell free supernatant is obtained by filtration or centrifugation of a Brevibacillus laterosporus fermentate. In one aspect, cells were removed from the Brevibacillus laterosporus fermentate by pelleting cells (centrifuge at 4,000 to 8,000 x g) and passing the supernatant through a 0.2 µM filter, to obtain an essentially cell-free supernatant. In one aspect, the fermentate extract for use in the present invention is a Brevibacillus laterosporus fermentate extract consisting essentially of cell free fermentate. The term "consisting essentially of" in the context of the fermentate includes that at least 90% of the fermentate have the indicated property (e.g. being cell free fermentate). Suitably at least 95% have the indicated property. Suitably at least 97% have the indicated property. Suitably at least 99% have the indicated property. In some embodiments at least 100% have the indicated property. The fermentate extract for use in the compositions and methods and / or uses of the present invention may be substantially free of viable Brevibacillus laterosporus cells, typically containing zero (or substantially zero) viable cells / mL fermentate. In another aspect, the fermentate extract is an extract of a cell pellet obtained from a fermentate by pelleting the cells. Cells pellets can be obtained by centrifugation of the fermentate and removing the cell free supernatant. In one aspect, the cell pellet extract is obtained from a Brevibacillus laterosporus fermentate by pelleting the cells (centrifuge at 4,000 to 8,000 x g) and pouring off the supernatant, to leave behind the portion of cell pellet. The pellet is resuspended in acidic water (1 / 10 v / v) to a pH 2.0 – 4.0, vortexed, pelleted by centrifugation (4,000 to 8,000 x g) and the extract liquid is passed through a 0.2 µM filter. Optionally, the cell pellet can be resuspended in alkaline water (1 / 10 v / v) at a pH higher than 8.5. The cell pellet can be suspended in any solution or under any condition that produces an effective amount of the fermentate extract solution. Starting from a cell pellet has the advantage that the volume of the resuspension liquid (extract volume) can be determined to produce an effective amount of the active extract and / or further concentrated to produce an effective amount of the active extract. Furthermore, resuspending the pellet in water or non-fermentation broth liquids, results in reducing or eliminating the non-active ingredients of the fermentation broth which may interfere with the actives of the cell pellet extract. In another aspect, Brevibacillus laterosporus fermentate extracts produced by combining the cell free supernatant fraction described above with the cell pellet extract described above. In yet another aspect, the Brevibacillus laterosporus fermentate is a fermentate extract that was prepared by first adjusting the pH of the fermentate (total fermentation broth) to a pH 2.0 - 4.0 prior to pelleting out the insoluble cellular matter and optionally filtering supernatant through a 0.2 µM filter to yield a cell free supernatant (also referred to as “whole broth fermentate extract”. The acid to make the pH adjustment can be hydrochloric acid, although any acid capable of adjusting the fermentation broth pH to 2.0-4.0 can be used. In preparing the whole broth fermentate extract of the Brevibacillus laterosporus fermentate in this way, it comprises the actives present in both the cell free supernatant and cell pellet extract described herein. Alternatively, the Brevibacillus laterosporus fermentate is a fermentate extract that was prepared by first adjusting the pH of the fermentate (total fermentation broth) to an alkaline pH prior to pelleting out the insoluble cellular matter and optionally filtering supernatant through a 0.2 µM filter to yield a cell free supernatant (also referred to as “whole broth fermentate extract”). In one aspect the fermentate extract is obtained from a fermentate that was produced with a nutrient medium having a pH between 2-12. In one aspect the fermentate extract is obtained from a fermentate wherein the pH of the fermentate was adjusted to a pH between 2-12, prior to obtaining the fermentate extract. Fermentate extracts can be further concentrated or purified prior to be included in a composition to obtain an effective amount of the fermentate extract. Fermentate extracts can be spray-dried or lyophilized prior to be include in a composition. It is also understood that production of a fermentate and fermentate extract can vary from batch to batch (fermentation to fermentation), which can result in different efficacies of the fermentate extract. As such batch to batch variation of the production of an effective amount of Brevibacillus laterosporus fermentate extracts can be observed. In one embodiment, the Brevibacillus laterosporus fermentate, fermentate extract, or composition comprising the fermentate extract is formulated in a dry formulation or a liquid formulation. In one embodiment, the Brevibacillus laterosporus fermentate, fermentate extract, or composition comprising the fermentate extract is formulated in at least one form selected from the group consisting of a loose or compact powder, a granule, a liquid suspension or solution, a spray solution, a gel, a roll on, a stick, a granulate, a soap bar, and a bath bomb or any combination thereof. Granules can be produced by any means known in the art, such as but not excluding, spray drying fermentate extract on a core or spray drying the fermentate to form a granule itself. In one aspect the granule is a readily dispersible layered granule. The layered granule can comprise a core surrounded by a coating layer that includes at least one effective amount of Brevibacillus laterosporus fermentate extract distributed within a protectant matrix, and wherein the core is water-soluble and fast dissolving. The protectant matrix can include at least one polyhydroxy compound and at least one phosphate compound. In one aspect the Brevibacillus laterosporus fermentate extract described herein is provided in a composition at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight relative to a total weight of said composition. In one aspect the Brevibacillus laterosporus fermentate extract described herein is provided in a composition at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition. In one aspect, the fermentate extracts, or fractions thereof, for use in the present invention includes fermentate extracts, or fractions thereof from the microorganism Brevibacillus laterosporus, wherein said Brevibacillus laterosporus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. Personal care compositions comprising Brevibacillus laterosporus fermentate extracts for malodor control The present disclosure includes Brevibacillus laterosporus fermentate extracts and compositions comprising an effective amount of Brevibacillus laterosporus fermentate extracts for malodor control. In one aspect, the inventors have unexpectedly observed that an effective amount of a Brevibacillus laterosporus fermentate extract functions as a malodor control agent to control body malodor. A “Brevibacillus malodor control agent” or “malodor control component” or “malodor mitigation component” is herein understood to be an effective amount of a Brevibacillus fermentate extract that is designed to prevent and / or reduce malodor and not function merely by covering up or masking odors. A genuine malodor control component provides a sensory and analytically measurable malodor reduction. As used herein, the term “malodor” refers to any odor that is not desired or intended on a body surface (such as, but not limited to, axillary body surface, skin, foot, hair and scalp) and compounds generally offensive or unpleasant to most people. Examples of malodor include volatile compounds with a perceived unpleasant smell, which may be produced by microorganisms. The microorganisms may be gram positive or gram-negative bacteria (aerobic or anaerobic); algae, protozoa, and / or yeast or filamentous fungi. In some embodiments the malodor may be associated with one or more microorganisms, including one or more bacterial genera of Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Pseudomonas sp. (e.g. Pseudomonas fluorescens), Staphylococcus sp. (e.g. Staphylococcus epidermidis), and Stenotrophomonas sp., Streptomyces sp., Listeria sp., Streptococcus sp., and Escherichia sp. Another example of malodor includes unpleasant smells which can be sweat, or body odor associated with an item that has been in contact with a human or animal. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface. In one aspect, the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface, wherein the body surface is selected from the group consisting of an axillary body surface (an axillary region of the body or underarm skin surface), skin, foot, hair and scalp. The body surface can be a human or animal body surface. In one embodiment, the composition is a malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface, wherein the composition is a personal care or cosmetic composition. In one embodiment, the malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract for preventing and / or reducing an axillary malodor is a deodorant composition. In one aspect the deodorant composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract for preventing and / or reducing a body malodor can be selected from the group consisting of a deodorant stick, a deodorant spray, a deodorant powder, and a roll on deodorant. In one aspect, the deodorant stick composition is a wax stick or an alcohol stick. In one aspect, the deodorant spray composition is an aerosol spray or a powder aerosol spray. In one embodiment, the composition is a deodorant composition for preventing or reducing body malodor, comprising, as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said effective amount of extract prevents and / or reduces a malodor on said body surface, and wherein the ingredient is incorporated in a vehicle for a deodorant. The malodor compositions or formulations described herein may be in the form of a spray, a liquid, a gel, a powder, a roll on, a stick, a granulate, a soap bar, and a bath bomb. In one embodiment, the composition is a deodorant composition comprising i) as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract; ii) a liquid carrier deodorant active; and optionally, iii) a fragrance. Malodor control can be determined by any means known to the art such as, but not limiting to evaluation of odorous compounds, or by evaluation from a sensory panel. In one embodiment, the malodor control composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition. In one embodiment, the malodor control composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 16.0%, 17.0%, 18.0%, 19.0%, 20%, 21%, 22%, 23%, 24%, 25.0%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight relative to a total weight of said composition. In one embodiment, the malodor control composition comprising the fermentate extract is formulated in a dry formulation or a liquid formulation. In one embodiment, the malodor control composition comprising the fermentate extract is formulated in at least one form selected from the group consisting of a loose or compact powder, a granule, a liquid suspension or solution, a spray solution, a gel, a roll on, a stick, a granulate, a soap bar, and a bath bomb and any combination thereof. In one embodiment, the malodor control composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein the Brevibacillus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non- sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. In one aspect, the inventors have unexpectedly observed that an effective amount of a Brevibacillus laterosporus fermentate extract functions as a cleaning agent. In one aspect of the disclosure, Brevibacillus fermentate extracts and cleaning compositions comprising an effective amount of a Brevibacillus fermentate extract are provided that prevent, reduce and / or remove sebum and / or soil on a soft surface such as a body surface. In one aspect the body surface is a human body surface or an animal body surface. A “Brevibacillus cleaning agent” or “cleaning agent” is herein understood to be an effective amount of Brevibacillus fermentate extract that is capable of preventing, reducing and / or removing substances associated with sebum (sweat) and other objectionable matter (known in cleaning terminology as 'soil') and / or preventing substances associated with sebum and soil to adhere to surfaces. In one embodiment, the Brevibacillus cleaning agent described herein is a sebum cleaning agent comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein the sebum cleaning agent prevents, reduces and / or removes sebum on a body surface such as but not limited to axillary body surface, skin, foot, hair and scalp. Such a Brevibacillus laterosporus fermentate extract can be selected from the group consisting of a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. In one embodiment, the composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents, reduces and / or removes sebum on a surface, wherein the composition is selected from the group consisting of a personal care composition. In one embodiment, the cleaning composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition. In one embodiment, the cleaning composition is a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100%by weight relative to a total weight of said composition. In one embodiment, the cleaning composition is a sebum cleaning composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein the Brevibacillus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. The terms “cleaning compositions” and “cleaning formulations” refer to admixtures of ingredients that find use in the prevention, reduction and / or removal of undesired compounds (e.g., soil or stains) from items or surfaces to be cleaned, such as, for example, hair, skin, teeth and mouth. The compositions or formulations may be in the form of a spray, a liquid, a gel, a powder, a roll on, a stick, a granulate, a soap bar, and a bath bomb. In one embodiment, the cleaning composition disclosed herein is a personal care composition It will be apparent that the composition for use according to the present invention may comprise an effective amount of a Brevibacillus laterosporus fermentate extract, for example, of at least about 0.01% to up to 100% by weight relative to a total weight of said composition. In one aspect, the composition comprises an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 16.0%, 17.0%, 18.0%, 19.0%, 20.0%, 21%, 22%, 23%, 24%, 25.0%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35.0%, 36%, 37%, 38%, 39%, 40.0%, 41%, 42%, 43%, 44%, 45.0%, 46%, 47%, 48%, 49%, 50.0%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight relative to a total weight of said composition. It will be further apparent that the composition for use according to the present invention may comprise an effective amount of a Brevibacillus laterosporus fermentate extract, for example, of at least about 0.01% to up to 100% by volume relative to a total volume of said composition. In one aspect, the composition comprises an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11.0%, 12.0%, 13.0%, 14.0%, 15.0%, 16.0%, 17.0%, 18.0%, 19.0%, 20.0%, 21%, 22%, 23%, 24%, 25.0%, 26%, 27%, 28%, 29%, 30.0%,31%, 32%, 33%, 34%, 35.0%, 36%, 37%, 38%, 39%, 40.0%, 41%, 42%, 43%, 44%, 45.0%, 46%, 47%, 48%, 49%, 50.0%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition. The personal care compositions of the present invention include, but are not limited to, cosmetic products (rinse-off cosmetic product, leave-on cosmetic products), aqueous solutions, emulsions, serums, jellies, patches, lotions, topical moisturizers, creams, pastes, balms, ointments, pomades, gels, liquids, sprays, foam, kits, or any one combinations thereof. As used herein, the term “rinse-off product” refers to a cosmetic product which is intended to be removed after application on the skin, the hair, or mucous membranes. Rinse-off products include, but are not limited to, shower gels, shampoos, rinse-off conditioners, shower additives (salts, foams, oil, gel), shaving foam, shaving cream, shaving gel, or shaving soap. As used herein, the term “leave-on product” refers to a cosmetic product which is intended to stay in prolonged contact with the skin, the hair, or the mucous membranes. Leave on products include, but are not limited to, make-up products, face creams, hair styling gels) In one aspect, the personal care composition of the present invention is formulated for topical administration to a human or animal body surface The topical formulation (personal care composition) for use in the present invention may be in any form suitable for application to the subject in need, such as a cream, lotion, sprays, solution, gel, ointment, paste, plaster, paint, bioadhesive, suspensions or the like, and / or may be prepared so as to contain liposomes, micelles, and / or microspheres. Such a formulation may be used in combination with an occlusive overlayer so that moisture evaporating from the body surface is maintained within the formulation upon application to the body surface and thereafter. Topical formulations include those in which the active ingredient(s) is (are) dissolved or dispersed in a dermatological vehicle known in the art (e.g. aqueous or non-aqueous gels, ointments, water-in-oil, or oil-in-water emulsions). Constituents of such vehicles may comprise water, aqueous buffer solutions, non-aqueous solvents (such as ethanol, isopropanol, benzyl alcohol, 2-(2-ethoxyethoxy) ethanol, propylene glycol, propylene glycol monolaurate, glycofurol or glycerol), oils (e.g. a mineral oil such as a liquid paraffin, natural or synthetic triglycerides, or silicone oils such as dimethicone). Depending, inter alia, upon the nature of the formulation as well as its intended use and site of application, the dermatological vehicle employed may contain one or more components (for example, when the formulation is an aqueous gel, components in addition to water) selected from the following list: a solubilizing agent or solvent (e.g. a β-cyclodextrin, such as hydroxypropyl β-cyclodextrin, or an alcohol or polyol such as ethanol, propylene glycol or glycerol);a thickening agent (e.g. hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose or carbomer);a gelling agent (e.g. a polyoxyethylene- polyoxypropylene copolymer);a traditional or soft preservative; and pH buffering agent(s) (such as a mixture of dihydrogen phosphate and hydrogen phosphate salts, or a mixture of citric acid and a hydrogen phosphate salt). A dermatologically or cosmetically acceptable carrier may also be incorporated in the personal care composition of the present invention and may be any carrier conventionally used in the art. Examples thereof include water, lower alcohols, higher alcohols, polyhydric alcohols, monosaccharides, disaccharides, polysaccharides, hydrocarbon oils, fats and oils, waxes, fatty acids, silicone oils, nonionic surfactants, ionic surfactants, silicone surfactants, and water-based mixtures and emulsion-based mixtures of such carriers. The term " dermatologically acceptable" or " dermatologically acceptable carrier" or “dermatologically acceptable excipient” is used herein to refer to a compound or composition that may be incorporated into a dermatologically or personal care formulation without causing undesirable biological effects or unwanted interaction with other components of the formulation. The term " cosmetically acceptable" or " cosmetically acceptable carrier" or “cosmetically acceptable excipient” is used herein to refer to a compound or composition that may be incorporated in a cometic formulation without causing undesirable biological effects or unwanted interaction with other components of the formulation. "Carriers" or "vehicles" as used herein refer to carrier materials suitable for incorporation in a topically applied composition. Carriers and vehicles useful herein include any such materials known in the art, which are nontoxic and do not interact with other components of the formulation in which it is contained in a deleterious manner. The term "aqueous" refers to a formulation that contains water or that becomes water-containing following application to the subject in need tissue (such as but not limiting to skin or mucosal tissue). Personal care composition of the present invention may further comprise one or more dermatologically acceptable components known or otherwise effective for use in personal care products, provided that the optional components are physically and chemically compatible with the essential components described herein, or do not otherwise unduly impair product stability, aesthetics, or performance. Non-limiting examples of such optional components are disclosed in International Skin Care Ingredient Dictionary, Ninth Edition, 2002, and CTFA Skin Care Ingredient Handbook, Tenth Edition, 2004. In one aspect, the dermatologically acceptable component is a dermatologically acceptable component comprising from about 10 wt.% to about 99.9 wt.%, alternatively from about 50 wt.% to about 95 wt.%, and alternatively from about 75 wt.% to about 95 wt.%, of a dermatologically acceptable carrier. Carriers suitable for use with the composition(s) may include, for example, those used in the formulation of mousses, tonics, gels, skin moisturizers and lotions. The carrier may comprise water; organic oils; silicones such as volatile silicones, amino or non-amino silicone gums or oils, and mixtures thereof; mineral oils; plant oils such as olive oil, castor oil, rapeseed oil, coconut oil, wheat germ oil, sweet almond oil, avocado oil, macadamia oil, apricot oil, safflower oil, candlenut oil, false flax oil, tamanu oil, lemon oil and mixtures thereof; waxes; and organic compounds such as C2-C10 alkanes, acetone, methyl ethyl ketone, volatile organic C1-C12 alcohols, esters of C1-C20 acids and of C1-C8 alcohols such as methyl acetate, butyl acetate, ethyl acetate, and isopropyl myristate, dimethoxyethane, diethoxyethane, C10-C30 fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol, and behenyl alcohol; C10-C30 fatty acids such as lauric acid and stearic acid; C10-C30 fatty amides such as lauric diethanolamide; C10-C30 fatty alkyl esters such as C10-C30 fatty alkyl benzoates; hydroxypropylcellulose, and mixtures thereof. In one aspect, the carrier comprises water, fatty alcohols, volatile organic alcohols, and mixtures thereof. Other carriers can be formulated by those of ordinary skill in the art. The personal care composition of the present invention described herein may further comprise from about 0.1% to about 10%, and alternatively from about 0.2% to about 5.0%, of a gelling agent to help provide the desired viscosity to the composition(s). Non-limiting examples of suitable optional gelling agents include alginates, xanthan gum, crosslinked carboxylic acid polymers; unneutralized crosslinked carboxylic acid polymers; unneutralized modified crosslinked carboxylic acid polymers; crosslinked ethylene / maleic anhydride copolymers; unneutralized crosslinked ethylene / maleic anhydride copolymers (e.g., EMA 81 commercially available from Monsanto); unneutralized crosslinked alkyl ether / acrylate copolymers (e.g., SALCARE™ SC90 commercially available from Allied Colloids); unneutralized crosslinked copolymers of sodium polyacrylate, mineral oil, and PEG-1 trideceth-6 (e.g., SALCARE™ SC91 commercially available from Allied Colloids); unneutralized crosslinked copolymers of methyl vinyl ether and maleic anhydride (e.g., STABILEZE™ QM-PVM / MA copolymer commercially available from International Specialty Products); hydrophobically modified nonionic cellulose polymers; hydrophobically modified ethoxylate urethane polymers (e.g., UCARE™ Polyphobe Series of alkali swellable polymers commercially available from Union Carbide); and combinations thereof. In this context, the term “unneutralized” means that the optional polymer and copolymer gelling agent materials contain unneutralized acid monomers. The dermatologically or cosmetically acceptable medium may contain a fatty substance in a proportion generally of from about 10 to about 90% by weight relative to the total weight of the product, where the fatty phase containing at least one liquid, solid or semi-solid fatty substance. The fatty substance includes, but is not limited to, oils, waxes, gums, and so-called pasty fatty substances. Alternatively, the products may be in the form of a stable dispersion such as a water-in-oil or oil-in-water emulsion. Additionally, the personal care products may contain one or more conventional cosmetic or dermatological additives or adjuvants, including but not limited to, antioxidants, preserving agents, fillers, surfactants, UVA and / or UVB sunscreens, fragrances, thickeners, wetting agents and anionic, nonionic or amphoteric polymers, and dyes or pigments (colorant agents). The dermatologically acceptable carrier may be a moisturizer formulation containing at least one emulsifier, at least one surfactant, or any combination thereof. Personal care compositions described herein can further comprise active ingredient materials including sun screen agents, moisturizers, humectants, benefiting agents skin, depositing agents such as surfactants, occlusive agents, moisture barriers, lubricants, emollients, anti-aging agents, antistatic agents, abrasive, antimicrobials, conditioners, exfoliants, fragrances, viscosifying agents, salts, lipids, phospholipids, vitamins, foam stabilizers, pH modifiers, preservatives, suspending agents, silicone oils, silicone derivatives, essential oils, oils, fats, fatty acids, fatty acid esters, fatty alcohols, waxes, polyols, hydrocarbons, and mixtures thereof. Any number of dermatologically acceptable materials commonly used in skin care products may also be incorporated into the present skin care products such as skin conditioning agents and skin colorants. Skin conditioning agents as herein defined include, but are not limited to astringents, which tighten skin; exfoliants, which remove dead skin cells; emollients, which help maintain a smooth, soft, pliable appearance; humectants, which increase the water content of the top layer of skin; occlusives, which retard evaporation of water from the skin’s surface; and miscellaneous compounds that enhance the appearance of dry or damaged skin or reduce flaking and restore suppleness. Skin conditioning agents are well known in the art, see for example Green et al. (WO01 / 07009), and are available commercially from various sources. Suitable examples of skin conditioning agents include, but are not limited to, lactobionic acid, gluconic acid, alpha- hydroxy acids, beta-hydroxy acids, polyols, hyaluronic acid, D,L-panthenol, polysalicylates, vitamin A palmitate, vitamin E acetate, glycerin, sorbitol, silicones, silicone derivatives, lanolin, natural oils, xylitol, fucose, rhamnose, and triglyceride esters. The skin conditioning agents may include polysalicylates, propylene glycol (CAS No.57-55-6, Dow Chemical, Midland, MI), glycerin (CAS No.56-81-5, Proctor & Gamble Co., Cincinnati, OH), glycolic acid (CAS No.79- 14-1, DuPont Co., Wilmington, DE), lactic acid (CAS No.50-21-5, Alfa Aesar, Ward Hill, MA), malic acid (CAS No.617-48-1, Alfa Aesar), citric acid (CAS No. 77-92-9, Alfa Aesar), tartaric acid (CAS NO.133-37-9, Alfa Aesar), glucaric acid (CAS No.87-73-0), galactaric acid (CAS No.526-99-8), 3-hydroxyvaleric acid (CAS No.10237-77-1), salicylic acid (CAS No.69-72-7, Alfa Aesar), and 1,3 propanediol (CAS No.504-63-2, DuPont Co., Wilmington, DE). Polysalicylates may be prepared by the method described by White et al. in U.S. Patent No. 4,855,483, incorporated herein by reference. Glucaric acid may be synthesized using the method described by Merbouh et al. (Carbohydr. Res.336:75-78 (2001). The 3-hydroxyvaleric acid may be prepared as described by Bramucci in published international patent application number WO 02 / 012530. In some embodiments, the compositions of the present invention further comprise materials including, but not limited to, one or more aqueous carriers, alcohol carriers, antiperspirant actives, base ingredients, emollients, solidification agents, hydration agents, emulsifiers, solubilizers, fragrances or perfumes, surfactants, thickening agents, salts, and any one combination thereof. In one aspect, the malodor control or cleaning composition described herein contains from 30% to 95%, alternatively 40% to 80%, alternatively 50% to 75% of an aqueous liquid carrier, in which the other essential and optional compositions components are dissolved, dispersed or suspended. Malodor control compositions, as provided herein, include, but are not limited to, granular, powder, liquid, gel, bar forms including deodorant products such as roll on deodorant, spray deodorant, aerosol spray deodorant, powder aerosol spray deodorant, pressed powder deodorant, wax stick deodorant and alcohol stick deodorants. Examples of deodorant model formulas for a roll on, spray, aerosol spray, Powder aerosol spray deodorant, pressed powder, wax stick and alcohol stick deodorants are shown in Tables 1A-1B. Table 1A. Deodorant model formulas for a roll on, spray, aerosol spray, and Powder aerosol spray deodorant. Deodorant model formula Function of Aerosol Powder (wt %)in redientsRoll on Sprays ra Aerosol Note : Aerosol spray has ratio of formulation:LPG (Liquefied Petroleum Gas)- 50:50; Powder aerosol spray ratio of formulation:LPG (Liquefied Petroleum Gas) -10:90 Table 1B. Deodorant model formulas for a pressed powder, wax stick and alcohol stick deodorant. Deodorant model formula Function of Pressed ngredientsWAlcohol (wt%) ipowderax stickstick In one aspect, the malodor control and cleaning compositions, as provided herein, include fragrances and / or perfumes. Fragrances, or perfumes, for use in the personal care compositions and methods herein include any fragrance / perfume available. There are no limitations on the type of composition in which perfumes may be incorporated. They may, for example, be included in compositions that are in the form of a spray, a liquid, a gel, a powder, a roll on, a stick, a granulate, a soap bar, and a bath bomb. Perfume components may be incorporated into compositions in physical forms and using methods known in the art, e.g. adding the perfume components as liquids, solid particles and / or microcapsules. Methods for providing malodor control The compositions described herein can be used in methods for providing malodor control. Methods are provided for the prevention and / or reduction of odor from body surfaces such as but not limiting to human or animal skin, scalp (hair) and feet. In one aspect, methods for preventing and / or reducing malodor on a body surface are provided, wherein the methods comprise contacting the body surface with an effective amount of a Brevibacillus laterosporus fermentate extract. Reduction in malodor may be measured by human sensory observations, such as by smelling the surface or solution, or by analytical measurement of malodorous compounds, such as but not limited to gas chromatography-mass spectrometry (GC / MS) or gas chromatography mass spectrometry with solid phase microextraction (GC / MS-SPME) or gas chromatography-olfactometry (GC-O). The surface can be contacted with an effective amount of a Brevibacillus laterosporus fermentate extract in a deodorant composition format. In some embodiments, the body surfaces are contacted with the effective amount of a Brevibacillus laterosporus fermentate extract or compositions comprising the effective amount of a Brevibacillus laterosporus fermentate extract under conditions for any amount of time desired or for any period of time sufficient to prevent and / or reduce odor on the surface. In one aspect, the disclosure provides methods for preventing, reducing or removing a malodor from a surface, wherein the methods comprise contacting a surface with an effective amount of a Brevibacillus fermentate extract or a composition comprising an effective amount of a Brevibacillus fermentate extract, and optionally rinsing said composition off of said item. In one embodiment, the method is a method of preventing or reducing a malodor from a body surface, comprising the step of applying an effective amount of a Brevibacillus laterosporus fermentate extract, or a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract to said body surface, wherein said extract prevents and / or reduces said malodor on said body surface. In one embodiment, the method is a method for preventing or reducing body malodor, the method comprising the step of applying to a body surface, preferably to an axillary skin, an effective amount of a Brevibacillus laterosporus fermentate extract or a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces said malodor on said body surface. In one aspect, the Brevibacillus laterosporus fermentate extract, or composition comprising the Brevibacillus laterosporus is applied to a human or an animal body surface. In one aspect, the Brevibacillus laterosporus fermentate extract, or composition comprising the Brevibacillus laterosporus is applied to an axillary region of a human or animal body surface. In one aspect, the Brevibacillus laterosporus fermentate extract, or composition comprising the Brevibacillus laterosporus is applied to an axillary body surface (an axillary region of the body or underarm skin surface), skin, foot, hair and scalp. In one embodiment, the method is a method of preventing or reducing a malodor from a body surface, comprising the step of applying an effective amount of a Brevibacillus laterosporus fermentate extract, or a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract to said body surface, wherein the application step comprises applying from 0.01% to 100% by weight of a Brevibacillus laterosporus fermentate extract, or a composition comprising from 0.01% to 100% by weight of a Brevibacillus laterosporus fermentate extract, to said body surface. In one embodiment, the method is a method of preventing or reducing a malodor from a body surface, comprising the step of applying a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100%by weight relative to a total weight of said composition, to said body surface. In one embodiment, the method is a method of preventing or reducing a malodor from a body surface, comprising the step of applying a composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition, to said body surface. In one aspect, the Brevibacillus laterosporus fermentate extract for use in the methods described herein is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. In one aspect, the Brevibacillus laterosporus fermentate extract for use in the methods described herein is obtained from a fermentate of a Brevibacillus laterosporus selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. General definitions The disclosures of all cited patent and non-patent literature are incorporated herein by reference in their entirety. In this disclosure, a number of terms and abbreviations are used. The following definitions apply unless specifically stated otherwise. As used herein, the articles “a”, “an”, and “the” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e., occurrences) of the element or component. Therefore “a”, “an”, and “the” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular. When an amount, concentration, or other value or parameter is given either as a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. Where a range of numerical values is recited herein, unless otherwise stated, the range is intended to include the endpoints thereof, and all integers and fractions within the range. It is not intended that the scope be limited to the specific values recited when defining a range. The use of numerical values in the various ranges specified in this application, unless expressly indicated otherwise, are stated as approximations as though the minimum and maximum values within the stated ranges were both proceeded by the word “about”. In this manner, slight variations above and below the stated ranges can be used to achieve substantially the same results as values within the ranges. Also, the disclosure of these ranges is intended as a continuous range including each and every value between the minimum and maximum values. As used herein, the term “about” modifying the quantity of an ingredient or reactant employed refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the compositions or carry out the methods; and the like. The term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term “about”, the claims include equivalents to the quantities. The term “aqueous,” as used in the phrases “aqueous composition” and “aqueous environment” refers to a composition that is made up of at least 50% water. An aqueous composition may contain at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% water. As used herein, the term “biological contaminants” refers to one or more unwanted and / or pathogenic biological entities including, but not limited to, microorganisms, spores, viruses, prions, and mixtures thereof. As used herein, the term “comprising” means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. The term “comprising” is intended to include embodiments encompassed by the terms “consisting essentially of” and “consisting of”. Similarly, the term “consisting essentially of” is intended to include embodiments encompassed by the term “consisting of”. As used herein, the term "cell lysate" or "lysate" refers to microbial cells which have been lysed by any suitable means. The term "cell lysate" or "lysate“ conventionally denotes a material obtained after the destruction or dissolution of biological cells via a phenomenon known as cell lysis, thus giving rise to the release of the intracellular biological constituents naturally contained in the cells of the microorganism under consideration. For the purposes of the present disclosure, the term “lysate” is used without preference to denote the whole lysate obtained via lysis of the microorganism under consideration or only a fraction thereof. The lysate used is thus totally or partially formed from the intracellular biological constituents and from the constituents of the cell walls and membranes. A lysate used for the invention may be the whole lysate obtained via lysis of the microorganism under consideration, or a fraction thereof. This cell lysis may be accomplished by any suitable means or any one method known in the art, such as but not limiting to, an osmotic shock, a heat shock, ultrasonication, sonication, homogenization, shearing, chemical lysis or under a mechanical stress of centrifugation type. In some embodiments, the cell debris is removed from the cell lysate prior to use. In some embodiments the cell lysates are filtered or fractionated prior to use. As used herein, "cleaning" means applying to a surface for the purpose of cleaning. The terms “clean surface” refer to a surface respectively that has a percent stain removal of at least 10%, preferably at least 15%, 20%, 25%, 30%, 35%, or 40% of a soiled surface. As used herein, the term “embodiment” or “disclosure” is not meant to be limiting but applies generally to any of the embodiments defined in the claims or described herein. These terms are used interchangeably herein. As used herein, the term “excipient” refers to inactive substance used as a carrier for active ingredients, in a formulation. The excipient may be used to stabilize the active ingredient in a formulation, such as the storage stability of the active ingredient. Excipients are also sometimes used to bulk up formulations that contain active ingredients. As used herein, the term “effective amount” refers to the amount sufficient to obtain the desired effect. When used in conjunction with a Brevibacillus fermentate extract, term “effective amount” refers to the quantity of a Brevibacillus fermentate extract needed to achieve the desired level of cleaning and / or malodor control activity in the specified composition. Such effective amounts are readily ascertained by one of ordinary skill in the art and are based on many factors, such as the particular Brevibacillus fermentate extract that is used, the malodor control or cleaning application, the specific composition of the malodor control or cleaning composition, and the form of (e.g., a spray, a liquid, a gel, a powder, a roll on, a stick, a granulate, a soap bar, and a bath bomb) composition is required. As used herein, the term “fragrance” or “perfume” includes raw materials and compositions, accords, scents and oils, for example essential oils. A wide variety of chemicals are known for fragrance (i.e., perfume) uses, including compounds such as aldehydes, ketones and esters. Also naturally occurring plant and animal oils and exudates comprising complex mixtures of various chemical components are known for use as fragrances. A perfume may be a blend of volatile compounds with different volatilities which can bind to receptors in the nose and therefore has a smell or odor, usually a pleasant one. These compounds are also known as odorants or fragrances. Most perfumes possess molar weights of up to approximately 200 g / mol, in some cases up to about 300 g / mol. Larger molecules are not volatile enough to be perceived by the human nose. The volatility of a compound describes how readily it vaporizes by way of evaporation or boiling. Perfume compounds vaporize, depending on their volatility, by evaporation at room temperature and atmospheric pressure. Volatility is often described using vapor pressure or boiling point, with a high vapor pressure or low boiling point indicating a high volatility. Although the volatility of a compound is related to its molecular weight, other factors such as structure and polarity also play a role, as does interaction between fragrance compounds. As used herein, the term “metabolite(s) thereof” or “metabolite(s) of the microorganism(s) suitable for use in the present invention “ or “metabolite actives” are used interchangeably and refer to any substance derived from the metabolism of a microorganism(s) suitable for use in the present invention As used herein, the term "soluble metabolite" refers to a metabolite or metabolites present in the supernatant of a cell culture (fermentate supernatant) from which the cells have been removed. In one embodiment the cells are removed by centrifugation. In one embodiment the supernatant is filtered. It will be apparent that the supernatant may be used directly in the formulations of the present invention, or that one or more of the metabolites may be isolated form the supernatant by any suitable means prior to use. As used herein, the term “"Neutralize" or "neutralization" refers to the ability of a compound or product to reduce or eliminate malodorous compounds. Odor neutralization may be partial, affecting only some of the malodorous compounds in a given context, or affecting only part of a malodorous compound. A malodorous compound may be neutralized by chemical reaction resulting in a new chemical entity, by sequestration, by chelation, by association, or by any other interaction rendering the malodorous compound less malodorous or non-malodorous. Odor neutralization may be distinguished from odor masking or odor blocking by a change in the malodorous compound, as opposed to a change in the ability to perceive the malodor without any corresponding change in the condition of the malodorous compound. As used herein, the term “reducing”, “reduces” and grammatical variations thereof in relation to a particular trait, characteristic, feature, biological process, or phenomena refers to a decrease in the particular trait, characteristic, feature, biological process, or phenomena. The trait, characteristic, feature, biological process, or phenomena can be decreased by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100% or greater than 100%. The terms “percent by weight”, “weight percentage (wt.%)” and “weight- weight percentage (% w / w)” are used interchangeably herein. Percent by weight refers to the percentage of a material on a mass basis as it is comprised in a composition, mixture, solution, or product. The terms “percent by volume”, “volume percentage” are used interchangeably herein. Percent by volume refers to the percentage of a material on a volume basis as it is comprised in a composition, mixture, solution, or product. The term “16S rRNA” or “16S ribosomal RNA” means the rRNA constituting the small subunit of prokaryotic ribosomes. In bacteria, this sequence can be used to identify and characterize operational taxonomic units. The term “ITS” or “Internal Transcribed Spacers” are regions within the ribosomal transcript that are excised and degraded during maturation. Their sequences can be used for phylogenetic analysis and / or identification of fungi or yeast. The term “percent (%) sequence identity” or “percent (%) sequence similarity,” as used herein with respect to a reference sequence is defined as the percentage of nucleotide residues in a candidate sequence that are identical to the residues in the reference polynucleotide sequence after optimal alignment of the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. A microbial “strain” as used herein refers to a microorganism (such as a bacterium or fungus) which remains genetically unchanged when grown or multiplied. The multiplicity of identical microbes is included. As used herein, the term a “biologically pure strain” means a strain containing no other microbial strains in quantities sufficient to interfere with replication of the strain or to be detectable by normal techniques. “Isolated” when used in connection with the organisms and cultures described herein includes not only a biologically pure strain, but also any culture of organisms which is grown or maintained other than as it is found in nature. As used herein, the term “probiotic” or “probiotic microorganism” are used interchangeably herein and refer to a live microorganism (including bacteria or yeasts for example) which, when administered (topically or orally) in sufficient amounts, beneficially affects the host organism, i.e. by conferring one or more demonstrable benefits, such as a reduced dandruff condition, on the host organism. Whilst there are no lower or upper limits for probiotic use, it has been suggested that at least 106-1012, preferably at least 106-1010, preferably 108-109, cfu as a daily dose will be effective to achieve the beneficial effects in a subject. The term “sequence identity” or “sequence similarity” as used herein, means that two polynucleotide sequences, a candidate sequence and a reference sequence, are identical (i.e.100% sequence identity) or similar (i.e. on a nucleotide-by-nucleotide basis) over the length of the candidate sequence. In comparing a candidate sequence to a reference sequence, the candidate sequence may comprise additions or deletions (i.e. gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for determining sequence identity may be conducted using the any number of publicly available local alignment algorithms known in the art such as ALIGN or Megalign (DNASTAR), or by inspection. As used herein, “surface” means any surface, including hard, soft, and porous surfaces. As used herein, the term “hard surface” refers to any article having a hard surface including, but not limiting to, floors, tables, walls, roofs, metal, glass, ceramics, wood, minerals (rock, stone, marble, granite), aggregate materials such as concrete, plastics, composite materials, hard rubber materials, and gypsum, as well as surfaces of hard objects such as cars, ship hulls, dishes (dishware), medical instruments, pipes, reservoirs, or holding tanks. The hard surface materials may be finished with enamels and paints. Hard surfaces are found, for example in kitchen tiles, bathroom tiles, water treatment and storage equipment and tanks; dairy and food processing equipment and facilities; medical equipment and facilities, such as surgical instruments and permanent and temporary implants; industrial pharmaceutical equipment and plants. The term “hard surface” also includes the surfaces of flexible yet firm objects such as the insides of bendable tubing and supply lines or the surfaces of deformable holding tanks or vessels. Soft surfaces are, for example, body surfaces such as axillary body surface, skin, foot, hair and scalp. Soft surfaces include human and animal body surfaces. Porous surfaces also may be found in certain ceramics as well as in membranes that are used for filtration. Other surfaces include, but are not limited to, ship hulls and swimming pools. Other surfaces may be biological surfaces, such as skin, keratin or internal organs. The term “surfactant” refers to any compound generally recognized in the art as having surface active qualities. Surfactants generally include anionic, cationic, nonionic, and zwitterionic compounds, which are further described, herein. It is intended that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Non-limiting examples of compositions and methods disclosed herein include: 1. A malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface. 2. The malodor control composition of embodiment 1, wherein the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. 3. The malodor control composition of embodiment 1, wherein the body surface is selected from the group consisting of an axillary region of the body, skin, foot, hair and scalp. 3b. The malodor control composition of embodiment 1 wherein the Brevibacillus laterosporus fermentate extract or the composition comprising the fermentate extract is formulated in a dry formulation or a liquid formulation. 3c. The malodor control composition of embodiment 1, wherein the Brevibacillus laterosporus fermentate, fermentate extract, or composition comprising the fermentate extract is formulated in at least one form selected from the group consisting of a loose or compact powder, a granule, a liquid suspension or solution, a spray solution, a gel, a roll on, a stick, a granulate, a soap bar, and a bath bomb or any combination thereof. 4. The malodor control composition of embodiment 1, wherein the composition is a personal care or cosmetic composition. 5. A personal care composition according to embodiment 4, wherein the composition is a deodorant composition. 6. The deodorant composition of embodiment 5, wherein the composition is a deodorant stick, a deodorant spray, a deodorant powder, or a roll on deodorant. 6b. The deodorant stick composition of embodiment 5, wherein the stick is a wax stick or an alcohol stick. 6c. The deodorant spray composition of embodiment 5, wherein the spray is an aerosol spray or a powder aerosol spray. 7. A deodorant composition for preventing or reducing body malodor, comprising, as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said effective amount of extract prevents and / or reduces a malodor on said body surface, and wherein the ingredient is incorporated in a vehicle for a deodorant. 7b. The deodorant composition of embodiment 5 or embodiment 7 wherein the composition is in the form of a spray, a liquid, a gel, a powder, a roll on, a stick, a granulate, a soap bar, and a bath bomb. 8. A deodorant composition comprising: i) as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract; ii) a liquid carrier deodorant active; and optionally, iii) a fragrance 9. The malodor control composition of embodiment 1 comprising from 0.01% to 100% by weight of a Brevibacillus laterosporus fermentate extract. 9b. The malodor control composition of embodiment 1 comprising an effective amount of Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume relative to a total volume of said composition. 9c. The malodor control composition of embodiment 1 comprising an effective amount of a Brevibacillus laterosporus fermentate extract at about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight relative to a total weight of said composition. 10. The composition any one of embodiments 1-9, further comprising an agent selected from the group consisting of an aqueous carrier, an alcohol carrier, an antiperspirant active, a base ingredient, an emollient, a solidification agent, a hydration agent, an emulsifier, a solubilizer, a fragrance, a surfactant, a thickening agent, a salt and any one combination thereof. 10b. The composition of any one of embodiments 1-10, wherein the Brevibacillus laterosporus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non- sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. 11. A method of preventing or reducing a malodor from a body surface comprising the step of applying a composition according to any one of embodiments 1-10 to said body surface. 11b. A method for preventing or reducing body malodor, the method comprising the step of applying to a body surface, preferably to an axillary skin, an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces said malodor on said body surface. 12. A method according to embodiment 11, wherein said composition is applied to a human or an animal body surface 12b. A method according to embodiment 12, wherein said composition is applied to an axillary region of the human or an animal body surface 13. A method according to embodiment 11, wherein said composition is applied to a human foot. 14. The method of any one of embodiments 11-13, wherein the application step comprises applying from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight of a Brevibacillus laterosporus fermentate extract, or a composition comprising from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by weight of a Brevibacillus laterosporus fermentate extract, to said body surface. 14b. The method of any one of embodiments 11-13, wherein the application step comprises applying from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume of a Brevibacillus laterosporus fermentate extract, or a composition comprising from about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or up to up to 100% by volume of a Brevibacillus laterosporus fermentate extract, to said body surface. 15. The method of any one of embodiments 11-14, wherein the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof. 16. The method of any one of embodiments 11-14, wherein the Brevibacillus laterosporus is selected from the group consisting of a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787. EXAMPLES In the following Examples, unless otherwise stated, parts and percentages are by weight and degrees are Celsius. It should be understood that these Examples, while indicating embodiments of the disclosure, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can make various changes and modifications of the disclosure to adapt it to various usages and conditions. Such modifications are also intended to fall within the scope of the appended claims. The following abbreviations in the specification correspond to units of measure, techniques, properties, or compounds as follows: “sec” or “s” means second(s), “min” means minute(s), “h” or “hr” means hour(s), “mL” means microliter(s), “mL” means milliliter(s), “L” means liter(s), “mM” means millimolar, “M” means molar, “mmol” means millimole(s), “uM” or “µM” measn micromolar, “ppm” means part(s) per million, “wt” means weight, “wt%” means weight percent, “g” means gram(s), “mg” means milligram(s), “mg” means microgram(s), “ng” means nanogram(s), “conc.” means concentration, “Trt” means treatment. EXAMPLE 1 Brevibacillus strains Brevibacillus suitable for use in the present invention includes, but are not limited to, a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-sporulating Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; and a Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788, Brevibacillus laterosporus having a 16S ribosomal RNA sequence displaying at least 97.0% sequence similarity to a 16S ribosomal RNA sequence of Brevibacillus laterosporus G11_1_1 (SEQ ID NO: 1) deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787, and any one combination thereof. Brevibacillus laterosporus strain G2 and G11_1_1 were isolated from a facial skin microbiome library prepared by swabbing the surface of facial skin, transferring to phosphate-buffered saline and serially diluted. Serial dilutions were plated onto petri dishes containing TSA (17g Tryptone, 3g Soytone, 5 g NaCl, 2.5g dipotassium phosphate, 2.5g glucose, 15g agar per liter distilled water) media. Plates were then incubated aerobically at 33 ºC until colonies became visible. Isolated colonies were the source for PCR reactions using standard protocols. The phylogenetic identity of Brevibacillus laterosporus strain G2 was determined by sequencing the 16S region with primer set A (SEQ ID NO: 2) where “M” is nucleotide Adenine or Cytosine and primer set B (SEQ ID NO: 3). Isolation of an endospore deficient strain^ Brevibacillus laterosporus is a rod-shaped, endospore-forming bacterium. It is not, however, desirable for endospores to be present in a final product or waste from industrial production. Therefore, it is preferred that the Brevibacillus laterosporus production strain is incapable of forming endospores. Eliminating endospore production was accomplished using a homologous recombination vector targeting the Stage II, sporulation protein E (spoIIE)gene of Brevibacillus laterosporus (SEQ ID NO: 4). The spoIIE locus of Bacillus subtilis is required for formation of a normal endospore through activation of the transcription factor sigma F (Barák I., Behari J., Olmedo G., Guzmán P., Brown D., Castro E., Walker D., Westpheling J., & Youngman P. (1996) Structure and function of the Bacillus SpoIIE protein and its localization to sites of sporulation septum assembly. Mol Microbiol.19(5):1047-60.). A truncated spoIIE gene was synthesized, by eliminating the first 600 bp, beginning with the initiation codon (SEQ ID NO: 5; Integrated DNA Technologies, Coralville, Iowa). The truncated gene was assembled into an integration vector (Leenhouts, K. J., et. al, 1991, Plasmid, 26(1), 55-66; Maguin, E., et al. ,1992. J Bacteriol, 174(17), 5633-5638) Successful integration, resulting in truncation of the spoIIE gene, was determined by PCR using the primer set primer set A2 (SEQ ID NO: 6) and primer set B2 (SEQ ID NO: 7). The deleted spoIIE sequence was confirmed by DNA sequencing. The absence of endospore production in the knockout strain was determined visually following growth in spore induction media and compared to the parent Brevibacillus laterosporus G2 strain (overnight cultures in TSB media were harvested by centrifugation and inoculated into sporulation medium (8 g / L Nutrient broth, 1 g / L KCl, 1 mM MgSO4, 1 mM Ca(NO3)2, 10 μM MnCl2, 1 μM FeSO4). Cells were grown at 33°C with agitation (200 rpm) and observed for production of spores after 48 hours). The spoIIE deletions strain, demonstrated to be endospore deficient, was designated Brevibacillus laterosporus A8.11 and deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Knockout of non-essential genes in Brevibacillus laterosporus Brevibacillus laterosporus strains contains genes associated with antibiotic resistance. In one aspect, elimination of genes that may confer resistance to antibiotics is desired, especially for Brevibacillus laterosporus production strains (strains used for large scale / commercial production of Brevibacillus laterosporus fermentates). Eliminating a series of genes related to Vancomycin resistance was accomplished using a homologous recombination vector targeting the entire operon (SEQ ID NO: 8). in Brevibacillus laterosporus A8.11 (CBS14109). A synthetic section of DNA was synthesized, corresponding to the genome directly upstream of the Vancomycin resistance genes linked directly to the downstream section, such that the synthetic sequence eliminates all intervening sequence containing the genes (SEQ ID NO: 9; Integrated DNA Technologies, Coralville, Iowa). The synthetic DNA construct was assembled into an integration vector (Leenhouts, K. J., et. al, 1991, Plasmid, 26(1), 55-66; Maguin, E., et al. ,1992. J Bacteriol, 174(17), 5633-5638). Successful assembly of the synthetic construct into the integration vector was determined by PCR using the primer set primer set A3(SEQ ID NO: 10) and primer set B3 (SEQ ID NO: 11). The deleted Vancomycin resistance operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 10 and SEQ ID NO: 11). Additional genes, potentially related to Vancomycin resistance, were removed using a homologous recombination vector targeting the location within the Brevibacillus laterosporus A8.11 genome (SEQ ID NO: 12). A synthetic section of DNA was synthesized, corresponding to the genome directly upstream of the putative Vancomycin resistance genes linked directly to the downstream section, such that the synthetic sequence eliminates all intervening sequence containing the genes (SEQ ID NO: 13; Integrated DNA Technologies, Coralville, Iowa). Successful assembly of the synthetic construct into the integration vector was determined by PCR using the primer set primer set C (SEQ ID NO: 14) and primer set D (SEQ ID NO: 15). The deleted Vancomycin resistance operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 14 and SEQ ID NO: 15). Brevibacillus laterosporus strains also contains genes associated with a virulence factor (Cytolysin). In one aspect, elimination of cytolysin genes is desired, especially for Brevibacillus laterosporus production strains. The cytolysin gene (SEQ ID NO: 16) was removed using a homologous recombination vector targeting its location within the Brevibacillus laterosporus genome. A synthetic section of DNA was synthesized, corresponding to the genome directly upstream of the cytolysin gene linked directly to the downstream section, such that the synthetic sequence eliminates all intervening sequence containing the genes (SEQ ID NO: 17; Integrated DNA Technologies, Coralville, Iowa). The synthetic DNA construct was assembled into an integration vector (Leenhouts, K. J., et. al, 1991, Plasmid, 26(1), 55-66; Maguin, E., et al. ,1992. J Bacteriol, 174(17), 5633-5638). Successful assembly of the synthetic construct into the integration vector was determined by PCR using the primer set primer set E (SEQ ID NO: 18) and primer set F (SEQ ID NO: 19). The deleted Vancomycin resistance operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 18 and SEQ ID NO: 19). Three Vancomycin and cytolysin deletions strains (confirmed by DNA sequencing as described above) were isolated from the last step of the three consecutive knockouts. The three strains were designated Brevibacillus laterosporus ALS311, Brevibacillus laterosporus ALS317, and Brevibacillus laterosporus ALS321, respectively, and deposited at Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785, CBS149786, CBS149788, respectively. EXAMPLE 2 Fermentates of Brevibacillus laterosporus Brevibacillus laterosporus strains were grown in TSB media (1.7% Tryptone, 0.3% Soytone, 0.25% Glucose, 0.5% sodium chloride, 0.25% Potassium phosphate Dibasic) in 250 ml baffled shake-flasks and incubated at 33 ºC, 250 RPM for 16-18 hours. Following the 16 to18-hour incubation, cells were transferred to fresh TSB media with optionally added glucose (10 g / L) or M9 media (0.64% Na2HPO4-7H2O, 0.15% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% glucose) or M9 media + Maltodextrin (0.64% Na2HPO4-7H2O, 0.15% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% Maltodextrin) or M9 media + Maltodextrin + urea (0.64% Na2HPO4-7H2O, 0.15% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% Maltodextrin, 5% urea) in 2L baffled flasks (final volume of 400 mL) to an optical density (absorbance at 600 nm), of 0.3. Cells were grown at 33 ºC and 90 RPM using AirOtop seals for 48 hours. Optionally the scale of the fermentation volume can be reduced or the length of fermentation can be increased to up to 4 days. To obtain larger volumes of fermentation broth (fermentate), fermentations were carried out in 500 mL bioreactors, 2L fermentation tanks, or 14L fermentation tanks. In the case of larger fermentation tanks, an antifoam such as Foamblast ® 882, Dystar International can be used. Brevibacillus laterosporus strains can be grown in any media that allows for cell growth. The fermentate (fermentation broth with mixture of culture medium and cells) was collected from the growth vessel after 48 hours incubation. EXAMPLE 3 Brevibacillus laterosporus fermentate extracts Extracts of the Brevibacillus laterosporus fermentates were obtained as described below. Cell free supernatants of Brevibacillus laterosporus fermentate Cells were removed from the Brevibacillus laterosporus fermentate, by pelleting cells (centrifuge at 4,000 to 8,000 x g) and passing the supernatant through a 0.2 µM filter, to obtain an essentially cell-free supernatant. Cell pellet extracts of Brevibacillus laterosporus fermentate A cell pellet extract from the Brevibacillus laterosporus fermentate was obtained by pelleting cells (centrifuge at 4,000 to 8,000 x g) and pouring off the supernatant, to leave behind the portion of cell pellet. The pellet was resuspended in acidic water (1 / 10 v / v) to a pH 2.5 – 4.0, vortexed, pelleted by centrifugation (4,000 to 8,000 x g) and the extract liquid was passed through a 0.2 µM filter. Starting from a cell pellet has the advantage that the volume of the resuspension liquid (extract volume) can be determined to produce an effective amount of the active extract and / or further concentrated to produce an effective amount of the active extract. Furthermore, resuspending the pellet in water or non-fermentation broth liquids, results in reducing or eliminating the non-active ingredients of the fermentation broth which may interfere with the actives of the cell pellet extract. Combination of Cell free supernatant and Cell pellet extracts of Brevibacillus laterosporus fermentate Brevibacillus laterosporus fermentate extracts were also produced by combining the cell free supernatant fraction described above with the cell pellet extract described above. Whole broth Brevibacillus laterosporus fermentate extracts To obtain a whole broth fermentate extract, the Brevibacillus laterosporus ferment extract was prepared by first adjusting the pH of the fermentate (total fermentation broth prepared as describe in Example 2) to a pH 2.5 - 4.0 prior to pelleting out the insoluble cellular matter and filtering supernatant through a 0.2 µM filter to yield a pH adjusted cell free supernatant. The preferred acid to make the pH adjustment is hydrochloric acid, although any acid capable of adjusting the fermentation broth pH to 2.5 can be used. In preparing the whole broth fermentate extract of the Brevibacillus laterosporus fermentate in this way, it comprises the actives present in both the cell free supernatant and cell pellet extract described above. Alternatively, the Brevibacillus laterosporus whole broth fermentate extract can be prepared by first adjusting the pH of the fermentate (total fermentation broth) to an alkaline pH prior to pelleting out the insoluble cellular matter and optionally filtering supernatant through a 0.2 µM filter to yield a cell free supernatant (also referred to as “whole broth fermentate extract”). EXAMPLE 4 Brevibacillus laterosporus fermentate extracts for malodor control of axillary odorous molecules produced by S. hominis. The ability of Brevibacillus laterosporus fermentate extracts to reduce and / or prevent malodor production was investigated. The B. laterosporus strain G11_1_1 was grown at 32oC for 28 hours in a shaking incubator (200 rpm) in a 125 ml vented flask with 25 ml tryptic soy broth medium (TSB). Cells were removed from the fermentate by centrifugation at 4000 rpm for 20 minutes, to obtain a cell-free supernatant (referred to as supernatant fermentate extract). The supernatant was filter-sterilized for use in the experiment. A second Brevibacillus laterosporus fermentate extract was obtained by resuspending the cell pellet to the original volume of the fermentate with TSB medium and the pH of the mixture was lowered to 2.0 using 4 N HCl to further extract activity. The pH of the cell pellet extract (referred to as cell pellet fermentate extract) was further adjusted back to 4.5 with 4 N NaOH before including in the odor production assay. Staphylococcus hominis (S. hominis) ATCC27844 was used as the target organism for malodor production. For the odor production assay, a 10 ml headspace vial with a screw cap with PTFE / blue silicone septum (Supelco, Pennsylvania, USA) was used. A fresh overnight culture of target organism S. hominis strain ATCC 27844 grown at 37oC in TSB was diluted in TSB medium to an OD (600 nm) of 0.2. In the assay, 3.7 ml of this diluted culture was added to each vial. The same amount of TSB medium was used as control. The experiment was performed in triplicates. The vials were placed in a plastic holder and incubated in a shaking incubator at 37oC at 200 rpm for 24 hours. After incubation, the volatiles in the headspace was analyzed by GC-MS. Gas chromatographic (GC) analyses were carried out with an Agilent 7890A gas chromatography with an Agilent 7000 mass spectrometer and equipped with a Gerstel MPS Robotic Pro autosampler. The divinylbenzene-carboxen-polydimethylsiloxane 50 / 30 μm (DVB / CAR / PDMS) SPME fiber was conditioned prior to use by insertion into the fiber conditioning module for 5 minutes at 280 ^C. The SPME program consisted of shaking the sample vial at 250 rpm at 60 °C for 5 min, then inserting the fiber into the headspace at 60 °C for 30 min, and then transferring the fiber to the GC injector for desorption at 250 °C for 2.5 min. GC injections were in splitless mode at 250 ^C for 2.5 min. An Agilent J&W HP- FFAP capillary column (30 m × 0.25 mm, and 0.25 μm film thickness) was used with helium carrier gas at constant flow of 1 ml / min. The oven temperature started at 40 °C and held for 2 min, and increased to 250 °C at a rate of 15 °C / min. A full scan mode (m / z 35–350) was applied for the identification of all the target compounds and to confirm the identify of peaks. Peak areas were calculated using Agilent MassHunter Qualitative analysis software. Table 2. Production of volatiles by S. hominis in the absence (control) or presence of either the supernatant fermentate extract of B. laterosporus (supernatant) or the cell pellet fermentate extract of B. laterosporus (cell pellet) as analyzed by GC-MS (integration of peak areas). Control Supernatant Cell Pellet pable of producing various volatile odorous compounds. These compounds included fatty acid and alcoholic molecules. Production of these compounds was reduced or prevented by the addition of the either the cell supernatant fermentate extract of B. laterosporus or the cell pellet fermentate extract of B. laterosporus. These results indicate the usefulness of these fermentate extracts for use in axillary malodor control applications. EXAMPLE 5 Effect of Brevibacillus laterosporus fermentate extracts on growth of S. hominis in the presence of callus. The ability of Brevibacillus laterosporus fermentate extracts to reduce and / or prevent the growth of S. hominis in the presence of callus was investigated. The callus-based skin stratum corneum model has been used to study the survival and growth of skin bacteria (van der Krieken, et al., Acta. Derm. Venereol.96:873-879, 2016). In this model, the human callus is used as substrate and nutrient for bacterial growth. Human callus from the heels (feet) was collected, mixed, frozen in liquid nitrogen and ground up. The B. laterosporus strain G11_1_1 was grown at 32oC for 28 hours in a shaking incubator (200 rpm) in a 125 ml vented flask with 25 ml tryptic soy broth medium (TSB). Cells were removed from the fermentate by centrifugation at 4000 rpm for 20 minutes, to obtain a cell free supernatant (referred to as supernatant fermentate extract). The supernatant (fermentate) was filter- sterilized for use in the experiment. A second Brevibacillus laterosporus fermentate extract was obtained by resuspending the cell pellet to the original volume of the fermentate with TSB medium and lowered the pH of the mixture to 2.0 using 4 N HCl to further extract activity. The pH of the extract (referred to as cell pellet fermentate extract) was adjusted to back to 4.5 with 4 N NaOH before assay. A STARTING culture of target organism S. hominis strain ATCC 27844 grown at 37oC in TSB was diluted in TSB medium to an OD (600 nm) of 0.2. In order to evaluate the impact of the Brevibacillus laterosporus G11_1_1 fermentate extracts on the growth of S. hominis, a callus assay was performed as described previously (van der Krieken, et al., 2026, Acta Derm. Venereol 96:873-879). The supernatant fermentate extract or cell pellet fermentate extract was added to the agar at a final concentration of 2% in a 24-well microtiter. To the top of the agar, 0.1 ml of 2% Callus suspension was added. After drying, 20 ul of overnight culture of S. hominis ATCC27844 at 1.0 OD (600 nm) was added. The plate was allowed to dry before incubating at 37oC for 48 hours. After incubation, the cells from each well were suspended with phosphate buffered saline (PBS) and plated onto TSB plates. The number of colonies was counted and the colonies forming unit (CFU / ml) was used to quantify the efficacy of growth prevention by the supernatant or cell extract. Table 3. Callus assay with S. hominis in the absence (control) or presence of either the supernatant fermentate extract of B. laterosporus (supernatant) or the cell pellet fermentate extract of B. laterosporus (cell pellet) CFU / ml C t l 42 106As show n n a e , t e contro without the supernatant or cell extract had a CFU count of 4.2 x106, while the CFU count was reduced to 2.0 x106, in the presence of the supernatant fermentate extract, suggesting the supernatant had moderate activity in preventing the growth of S. hominis in the callus assay. In the presence of cell pellet fermentate extract, on the other hand, no viable cells were observed, indicating strong growth preventing activity of the cell pellet fermentate extract. EXAMPLE 6 Brevibacillus laterosporus fermentate extracts for malodor control of feet odor. The ability of Brevibacillus laterosporus fermentate extracts to reduce and / or prevent foot malodor was investigated. Isovaleric acid is a key component of foot malodor. (Katsutoshi Ara et al., 2006, Can J Microbiol., 52(4):357-64). The conversion of leucine to isovaleric acid is known in the industry as a method of controlling malodor production. (S. Mayer et al., 2021, MicrobiologyOpen V10, issue 2.) and this test method can be used to test for malodor reduction. The method was modified to test for general reduction in isovaleric acid production in the presence and absence of a Brevibacillus laterosporus fermentate extract as described below. A cell free supernatant of a Brevibacillus laterosporus fermentate (e.g. Brevibacillus laterosporus fermentate extract) was prepared as described in Example 3. Samples with and without the Brevibacillus laterosporus cell free supernatant were prepared. Each sample was made by adding either 1 mL of tryptic soy broth (TSB) or 1 mL of cell free supernatant, 1 mL of Staphylococcus aureus ATCC #6538 overnight in TSB, and 13 mL of growth media. The growth medias were chosen from TSB, a Casamino Acid based broth (10g / L Casamino Acids in sterile water pH adjusted to 7), or an Eccrine sweat purchased from Pickering Laboratories. Solid phase micro extraction (SPME) vials were loaded with 4 mL of sample, pulling from the original sample to get three identical sample vials for analysis. The SPME vials were placed in a 33oC static incubator for 48 hours before GC-MS analysis using a SPME fiber. This gave the samples a chance to produce the isovaleric acid, representing the foot malodor. Gas chromatographic analyses were carried out with an Agilent 7890A gas chromatography with an Agilent 7000 mass spectrometer and equipped with a Gerstel MPS Robotic Pro autosampler. The divinylbenzene-carboxen- polydimethylsiloxane 50 / 30 μm (DVB / CAR / PDMS) SPME fiber was conditioned prior to use by insertion into the fiber conditioning module for 5 minutes at 280°C. The SPME program consisted of shaking the sample vial at 250 rpm at 60 °C for 5 min, then inserting the fiber into the headspace at 60 °C for 30 min, and then transferring the fiber to the GC injector for desorption at 250 °C for 2.5 min. GC injections were in splitless mode at 250°C for 2.5 min. An Agilent J&W HP-FFAP capillary column (30 m × 0.25 mm, and 0.25 μm film thickness) was used with helium carrier gas at constant flow of 1 ml / min. The oven temperature started at 40 °C and held for 2 min, and increased to 250 °C at a rate of 15 °C / min. A full scan mode (m / z 35–350) was applied for the identification of all the target compounds and to confirm the identify and retention time of isovaleric acid. For quantitation, the mass spectrometer was operated in electron ionization mode at 70 eV with selected-ion-monitoring (SIM) mode monitoring 41.1 m / z, 60 m / z, and 87 m / z ions. The retention time of isovalerate was 10.33 minutes. Peak areas were calculated using Agilent MassHunter Qualitative analysis software. The TSB media blank, Eccrine sweat blank, Casamino acid blank samples were analyzed by GC-MS under the selected ion monitoring conditions described above. No peaks appear at the 10.329 minute retention time in any of the blanks suggesting that the blanks were free of detectable levels of isovaleric acid. The various samples (in triplicate) were analyzed by GC-MS using selective ion monitoring as described above. Isovaleric acid was detected in all of the samples. In general, samples without cell free supernatant had significantly higher levels of isovaleric acid compared to those samples with cell free supernatant. (Table 4). Table 4. Levels of Isovaleric Acid Detected Samples with and without cell free supernatant. Sample Type Average Peak Standard n Casamino Acid 1159456 1396594 Broth with cell free etected in the samples without cell free supernatant than the samples with the cell free supernatant. This suggests that the cell free supernatant was able to reduce the amount of isovaleric acid produced in the samples. Since isovaleric acid is a key component of foot malodor, the cell free supernatant can be used to reduce foot malodor.

Claims

THAT WHAT IS CLAIMED:

1. A malodor control composition comprising an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said extract prevents and / or reduces a malodor on a body surface.

2. The malodor control composition of claim 1, wherein the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from a Brevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof.

3. The malodor control composition of claim 1, wherein the body surface is selected from the group consisting of an axillary region of the body, skin, foot, hair and scalp.

4. The malodor control composition of claim 1, wherein the composition is a personal care or cosmetic composition.

5. The malodor control composition of claim 1 wherein the Brevibacillus laterosporus fermentate extract or the composition comprising the fermentate extract is formulated in a dry formulation or a liquid formulation.

6. A personal care composition according to claim 4, wherein the composition is a deodorant composition.

7. The deodorant composition of claim 6, wherein the composition is a deodorant stick, a deodorant spray, a deodorant powder, or a roll on deodorant.

8. A deodorant composition for preventing or reducing body malodor, comprising, as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract, wherein said effective amount of extract prevents and / or reduces a malodor on said body surface, and wherein the ingredient is incorporated in a vehicle for a deodorant.

9. A deodorant composition comprising: i) as a deodorant active ingredient an effective amount of a Brevibacillus laterosporus fermentate extract; ii) a liquid carrier deodorant active; and optionally, iii) a fragrance 10. The composition of claim 1 or claim 4, further comprising an agent selected from the group consisting of an aqueous carrier, an alcohol carrier, an antiperspirant active, a base ingredient, an emollient, a solidification agent, a hydration agent, an emulsifier, a solubilizer, a fragrance, a surfactant, a thickening agent, a salt and any one combination thereof.

11. A method of preventing or reducing a malodor from a body surface comprising the step of applying a composition according to claim 1 or claim 4 to said body surface.

12. A method according to claim 11, wherein said composition is applied to a human or an animal body surface.

13. A method according to claim 11, wherein said composition is applied to an axillary body surface, skin, foot, hair or scalp.

14. The method of claim 12, wherein the Brevibacillus laterosporus fermentate extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus fermentate, a cell free supernatant obtained from aBrevibacillus laterosporus fermentate, a whole broth fermentate extract obtained from a Brevibacillus laterosporus fermentate, and any one combination thereof.

Images